abstract |
The present invention relates to a pharmaceutical nanoparticulate tachykinin receptor antagonist composition. The present invention relates to a novel pharmaceutical composition which is 2 (R) - (1- (R) - (3,5-histrifluoromethyl-phenyl) -ethoxy) -3- (S) - (4-fluoro) - Contains phenyl-4- (3- (5-oxo-1H, 4H-1,2,4-triazolo) methyl-morpholine. This medicinal product is useful in the treatment or prevention of psychiatric disorders such as depression, anxiety, inflammatory diseases and vomiting: |